Cargando…

The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer

BACKGROUND: Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Xianyuan, Guo, Qiusheng, Pan, Zhiwen, Xu, Xiaohong, Shao, Xiying, Wang, Xiaojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422094/
https://www.ncbi.nlm.nih.gov/pubmed/34532469
http://dx.doi.org/10.21037/atm-21-3848
_version_ 1783749217779449856
author Miao, Xianyuan
Guo, Qiusheng
Pan, Zhiwen
Xu, Xiaohong
Shao, Xiying
Wang, Xiaojia
author_facet Miao, Xianyuan
Guo, Qiusheng
Pan, Zhiwen
Xu, Xiaohong
Shao, Xiying
Wang, Xiaojia
author_sort Miao, Xianyuan
collection PubMed
description BACKGROUND: Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseases. The binding of T-cell immunoglobulin mucin 3 (TIM-3) and its ligand on the surface of Tfr cells could result in the depletion of T lymphocytes and the termination of the immune response mediated by helper T cell 1. However, the role of Tfr cells in breast cancer (BC) remains unclear. METHODS: In this study, we detected the expression of CD4+CXCR5+Foxp3+Tfr cells in the peripheral blood of 35 BC patients and 30 healthy control patients by flow cytometry, and analyzed the relationship between Tfr cells and the clinical characteristics of patients. In addition, the expression of TIM-3 on the surface of Tfr cells in 6 triple-negative BC (TNBC) patients was further investigated using mass spectrometry. RESULTS: We found a significant increase in Tfr cells in BC patients compared to healthy control patients (23.47%±9.70% vs. 10.99%±4.68%; P=0.001). Notably, the increase was more significant in early stage than advanced stage TNBC patients (28.52%±10.75% vs. 18.69%±5.19%; P=0.006), and there was a negative correlation between Tfr cells and serum lactate dehydrogenase (LDH) in early stage TNBC patients (r=−0.585; P=0.008). Additionally, we found that the expression of Tfr cells was higher in TNBC patients than luminal BC patients (28.25%±10.11% vs. 18.5%±8.15%; P=0.028); however, there was no significant difference in expression in hormone receptor positive (HR+) BC and hormone receptor negative (HR−) BC (P=0.141) patients. Notably, the surface of Tfr cells of TNBC patients had higher levels of TIM-3 expression than those of healthy control patients (3.93±0.92 vs. 2.65±0.15, respectively; t=−3.02; P<0.05), which the mass spectrometry showed were positively correlated with the intracellular Foxp3 expression of Tfr cells (r=0.82; P=0.036). CONCLUSIONS: Our results suggest that circulating Tfr cells and the expression of TIM-3 were significantly increased in BC patients, which were related to stage and histological type, and may be involved in the pathogenesis of BC.
format Online
Article
Text
id pubmed-8422094
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-84220942021-09-15 The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer Miao, Xianyuan Guo, Qiusheng Pan, Zhiwen Xu, Xiaohong Shao, Xiying Wang, Xiaojia Ann Transl Med Original Article BACKGROUND: Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseases. The binding of T-cell immunoglobulin mucin 3 (TIM-3) and its ligand on the surface of Tfr cells could result in the depletion of T lymphocytes and the termination of the immune response mediated by helper T cell 1. However, the role of Tfr cells in breast cancer (BC) remains unclear. METHODS: In this study, we detected the expression of CD4+CXCR5+Foxp3+Tfr cells in the peripheral blood of 35 BC patients and 30 healthy control patients by flow cytometry, and analyzed the relationship between Tfr cells and the clinical characteristics of patients. In addition, the expression of TIM-3 on the surface of Tfr cells in 6 triple-negative BC (TNBC) patients was further investigated using mass spectrometry. RESULTS: We found a significant increase in Tfr cells in BC patients compared to healthy control patients (23.47%±9.70% vs. 10.99%±4.68%; P=0.001). Notably, the increase was more significant in early stage than advanced stage TNBC patients (28.52%±10.75% vs. 18.69%±5.19%; P=0.006), and there was a negative correlation between Tfr cells and serum lactate dehydrogenase (LDH) in early stage TNBC patients (r=−0.585; P=0.008). Additionally, we found that the expression of Tfr cells was higher in TNBC patients than luminal BC patients (28.25%±10.11% vs. 18.5%±8.15%; P=0.028); however, there was no significant difference in expression in hormone receptor positive (HR+) BC and hormone receptor negative (HR−) BC (P=0.141) patients. Notably, the surface of Tfr cells of TNBC patients had higher levels of TIM-3 expression than those of healthy control patients (3.93±0.92 vs. 2.65±0.15, respectively; t=−3.02; P<0.05), which the mass spectrometry showed were positively correlated with the intracellular Foxp3 expression of Tfr cells (r=0.82; P=0.036). CONCLUSIONS: Our results suggest that circulating Tfr cells and the expression of TIM-3 were significantly increased in BC patients, which were related to stage and histological type, and may be involved in the pathogenesis of BC. AME Publishing Company 2021-08 /pmc/articles/PMC8422094/ /pubmed/34532469 http://dx.doi.org/10.21037/atm-21-3848 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Miao, Xianyuan
Guo, Qiusheng
Pan, Zhiwen
Xu, Xiaohong
Shao, Xiying
Wang, Xiaojia
The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
title The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
title_full The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
title_fullStr The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
title_full_unstemmed The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
title_short The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
title_sort characteristics and novel clinical implications of cd4+cxcr5+foxp3+ follicular regulatory t cells in breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422094/
https://www.ncbi.nlm.nih.gov/pubmed/34532469
http://dx.doi.org/10.21037/atm-21-3848
work_keys_str_mv AT miaoxianyuan thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT guoqiusheng thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT panzhiwen thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT xuxiaohong thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT shaoxiying thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT wangxiaojia thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT miaoxianyuan characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT guoqiusheng characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT panzhiwen characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT xuxiaohong characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT shaoxiying characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer
AT wangxiaojia characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer